DE69829469D1 - Verfahren und konjugat zur behandlung von helicobacter pylori-infektionen - Google Patents

Verfahren und konjugat zur behandlung von helicobacter pylori-infektionen

Info

Publication number
DE69829469D1
DE69829469D1 DE69829469T DE69829469T DE69829469D1 DE 69829469 D1 DE69829469 D1 DE 69829469D1 DE 69829469 T DE69829469 T DE 69829469T DE 69829469 T DE69829469 T DE 69829469T DE 69829469 D1 DE69829469 D1 DE 69829469D1
Authority
DE
Germany
Prior art keywords
conjugate
pylori
transport
subject
helicobacter pylori
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69829469T
Other languages
English (en)
Inventor
L Iversen
Randall Brand
D Weller
E Summerton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska
Sarepta Therapeutics Inc
Original Assignee
AVI Biopharma Inc
University of Nebraska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/848,844 external-priority patent/US6030941A/en
Application filed by AVI Biopharma Inc, University of Nebraska filed Critical AVI Biopharma Inc
Application granted granted Critical
Publication of DE69829469D1 publication Critical patent/DE69829469D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69829469T 1997-01-24 1998-01-23 Verfahren und konjugat zur behandlung von helicobacter pylori-infektionen Expired - Lifetime DE69829469D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3636697P 1997-01-24 1997-01-24
US08/848,844 US6030941A (en) 1996-05-01 1997-04-30 Polymer composition for delivering substances in living organisms
PCT/US1998/001393 WO1998032467A2 (en) 1997-01-24 1998-01-23 Method and conjugate for treating h. pylori infection

Publications (1)

Publication Number Publication Date
DE69829469D1 true DE69829469D1 (de) 2005-04-28

Family

ID=26713116

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69829469T Expired - Lifetime DE69829469D1 (de) 1997-01-24 1998-01-23 Verfahren und konjugat zur behandlung von helicobacter pylori-infektionen

Country Status (8)

Country Link
US (1) US6124271A (de)
EP (1) EP0973886B1 (de)
JP (1) JP2001509167A (de)
AT (1) ATE291617T1 (de)
AU (1) AU742521B2 (de)
CA (1) CA2278924A1 (de)
DE (1) DE69829469D1 (de)
WO (1) WO1998032467A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
WO1996001273A1 (en) * 1994-07-01 1996-01-18 Rican Limited Helicobacter pylori antigenic protein preparation and immunoassays
GB2324093A (en) * 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
GB9807721D0 (en) * 1998-04-08 1998-06-10 Chiron Spa Antigen
US6190667B1 (en) * 1998-06-30 2001-02-20 Institut Pasteur Methods of inhibiting Helicobacter pylori
AU6258999A (en) * 1998-09-16 2000-04-03 Vitagenix, Inc. Compositions and methods of use of uptake mechanisms for diagnostic and therapeutic applications of oligonucleotides targeting bacteria
HUP0203465A2 (hu) * 1998-11-11 2003-01-28 Pantheco A/S Peptidek és nukleinsav-analóg, mint például PNS, LNS vagy morfolino közötti konjugátumok
US6548651B1 (en) 1998-11-11 2003-04-15 Pantheco A/S Modified peptide nucleic acid (PNA) molecules
AUPQ051099A0 (en) * 1999-05-24 1999-06-17 Tachas, George Dr Novel products and processes in treatment and/or prophylaxis
KR20020064915A (ko) 1999-11-29 2002-08-10 에이브이아이 바이오파마 인코포레이티드 안티센스 항박테리아 방법 및 조성물
AU781676B2 (en) * 2000-01-04 2005-06-02 Avi Biopharma, Inc. Antisense antibacterial cell division composition and method
GB0005743D0 (en) * 2000-03-10 2000-05-03 Reckitt & Colmann Prod Ltd Pharmaceutical compositions including alginates
CA2458854A1 (en) * 2001-08-31 2003-03-06 Chiron Srl Helicobacter pylori vaccination
ATE510914T1 (de) 2004-07-02 2011-06-15 Avi Biopharma Inc Antisinn antibakterielle verfahren und verbindungen
EP1935434A1 (de) * 2006-12-19 2008-06-25 Novosom AG Konstruktion und Verwendung von transfektionsverstärkenden Elementen
US9914745B2 (en) 2009-08-14 2018-03-13 Indian Association For The Cultivation Of Science Morpholino-based antisense agent
US9050373B2 (en) 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
JP2014507143A (ja) 2011-02-08 2014-03-27 ザ シャーロット−メクレンバーグ ホスピタル オーソリティ ドゥーイング／ビジネス／アズ キャロライナズ ヘルスケア システム アンチセンスオリゴヌクレオチド
US20150050245A1 (en) * 2013-08-14 2015-02-19 Tntgamble, Inc. Methods and delivery system for beneficial additive and subtractive biological agents to promote balanced mammalian gastrointestinal flora
EP3302489A4 (de) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. Verfahren und verbindungen zur behandlung von krankheiten und leiden im zusammenhang mit lymphozyten
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
KR20230110501A (ko) * 2020-10-01 2023-07-24 미시시피 주립대학 육탄당 인산염과 접합된 약물 및 이를 제조하고 사용하는 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
WO1993010820A1 (en) * 1991-11-26 1993-06-10 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5409903A (en) * 1992-02-18 1995-04-25 Urecap Corporation Method and compositions for the treatment of H. pylori and dermatitis
US5426025A (en) * 1992-05-28 1995-06-20 Florida State University Species-specific DNA probes for vibrio vulnificus methods and kits
US5434257A (en) * 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5574142A (en) * 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
EP0653438A3 (de) * 1993-08-06 1995-10-18 Takeda Chemical Industries Ltd Oligonukleotid Verbindungen ihre Herstellung und ihre Verwendung.
US5434253A (en) * 1994-03-21 1995-07-18 Vanderbilt University DNA encoding Helicobacter pylori recombinase
GB9505438D0 (en) * 1995-03-17 1995-05-03 Sod Conseils Rech Applic Antisense oligonucleotides
JP2000509394A (ja) * 1996-05-01 2000-07-25 アンティバイラルズ インコーポレイテッド 細胞膜を横切って物質を輸送するためのポリペプチド結合体

Also Published As

Publication number Publication date
EP0973886A2 (de) 2000-01-26
WO1998032467A2 (en) 1998-07-30
AU5930598A (en) 1998-08-18
WO1998032467A3 (en) 1998-09-17
US6124271A (en) 2000-09-26
AU742521B2 (en) 2002-01-03
JP2001509167A (ja) 2001-07-10
EP0973886B1 (de) 2005-03-23
ATE291617T1 (de) 2005-04-15
CA2278924A1 (en) 1998-07-30

Similar Documents

Publication Publication Date Title
ATE291617T1 (de) Verfahren und konjugat zur behandlung von helicobacter pylori-infektionen
NO20033351L (no) Fremgangsmater for a indusere organtransplantasjontoleranse og korrigering av hemoglobinopatier
DK1242438T3 (da) Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse
Noller Peptidyl transferase: protein, ribonucleoprotein, or RNA?
ATE406453T1 (de) Verfahren zür einführung und expression von genen in tierischen zellen
PT1077688E (pt) Sistema terapeutico transdermico contendo pergolide
GB8613481D0 (en) Translation of mrna
TR200001736T2 (tr) Dikkat noksanlığı rahatsızlığının tedavisi için yöntem ve terkipler.
DE69914932D1 (de) Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
WO2003068144A3 (en) Cytotoxic agents
ATE332918T1 (de) Neoglycoproteine
NO974194L (no) Forbedringer i, eller vedrörende, organiske sammensetninger
PE20030400A1 (es) Productos en gel para la axila con componentes de bloque de agua
DK1681355T3 (da) Sekvensspecifik DNA-rekombination i eukaryote celler
RU94045151A (ru) Биоразлагаемые полимеры и способ их получения
DK1242012T3 (da) Forbedret transdermalt præventionsmiddelafgivelsessystem og fremgangsmåde
PT1117390E (pt) Sistemas de distribuicao de farmacos originarios da mucosa e aplicacoes em animais
EP0838224A3 (de) Polymer - Arzneimittel Konjugate mit einer enzymspaltbaren Linker
WO2000047231A3 (en) Novel antisense inhibition of rad51
WO1999027086A1 (en) Chimeric antisense oligonucleotides against tnf-alpha and their uses
Parekh et al. Pancreatic regeneration after partial pancreatectomy
WO1997046673A3 (en) Inhibition of hiv-1 replication by antisense rna expression
NO20014815L (no) Fremstilling av pankreatisk prokarboksypeptidase B, isoformer og muteiner derav og deres anvendelse
ATE235909T1 (de) Biologisch kompatible und biologisch abbaubare zubereitungen enthaltend hyaluronsäure und deren derivate zur behandlung von geschwüren im verdauungsapparat
DK1135164T3 (da) Sammensætning til behandling af inflammation

Legal Events

Date Code Title Description
8332 No legal effect for de